{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-014424","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.285881+00:00","generated_at":"2026-06-16T16:32:45.754948+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Finch Therapeutics replaces CEO and CFO; Blischak appointed CEO effective May 16","bullets":["CEO Mark Smith and COO Marc Blaustein terminated without cause, effective May 15, 2023; Smith resigns from board.","Matthew P. Blischak named CEO effective May 16; base salary $400k, target bonus 40%, option grant of 962,899 shares.","Lance Thibault (Danforth Advisors) named CFO effective May 16; paid hourly $525.","Former executives to remain as consultants under advisory agreements.","Company emphasizes foundational IP estate (over 70 issued patents) as key asset."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-014424","json":"https://secwatch.observer/filing/0000950170-23-014424.json","markdown":"https://secwatch.observer/filing/0000950170-23-014424.md","text":"https://secwatch.observer/filing/0000950170-23-014424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/0000950170-23-014424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/fnch-20230421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T16:32:45.754948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09fc3df571","claim":"Matthew P. Blischak was appointed as Chief Executive Officer at Finch Therapeutics Group, Inc..","evidence_excerpt":"Additionally, on April 21, 2023, and effective as of May 16, 2023, the Board appointed Matthew P. Blischak to serve as the Company’s Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/0000950170-23-014424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"2c12eb08cf","claim":"Marc Blaustein was terminated as Chief Operating Officer at Finch Therapeutics Group, Inc..","evidence_excerpt":"On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/0000950170-23-014424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"55030ada2a","claim":"Mark Smith resigned as Director at Finch Therapeutics Group, Inc..","evidence_excerpt":"Further, on April 21, 2023, Dr. Smith resigned as a member of the Board, effective as of May 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/0000950170-23-014424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"892d8be235","claim":"Lance Thibault was appointed as Chief Financial Officer at Finch Therapeutics Group, Inc..","evidence_excerpt":"and Lance Thibault to serve as the Company’s Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/0000950170-23-014424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"9d0534ea37","claim":"Mark Smith was terminated as Chief Executive Officer at Finch Therapeutics Group, Inc..","evidence_excerpt":"On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/0000950170-23-014424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}